Mechanical alternans, an ominous sign of terminal systolic heart failure, could be indirectly shown by Doppler analysis. On the other hand, Levosimendan, a novel agent, improves contractility in patients with HE We searched the effect of L versus dobutamin onto Doppler alternans in patients with systolic HE We found that Levosimendan improves beta-to-beat alteration in patients with systolic HF, demonstrated by pulsed Doppler compared to dobutamin. (C) 2007 Elsevier Ireland Ltd. All rights reserved
BackgroundLevosimendan is a new inodilatory agent with calcium sensitizing activity. A major concern...
International audienceLevosimendan is a new inodilatory agent with calcium sensitizing activity. A m...
Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosime...
Mechanical alternans, an ominous sign of terminal systolic heart failure, could be indirectly shown ...
PubMed ID: 18786088Introduction: Although beta-blockers are highly effective in the treatment of hea...
Severe heart failure represents a major source of morbidity and mortality. Poor right ventricular fu...
WOS: 000252322200014PubMed ID: 17949428Objectives: Levosimendan is a novel positive inotropic calciu...
Background: Previous studies comparing levosimendan vs. dobutamine have revealed that levosimendan i...
In heart failure, positive inotropes that increase the heart's energy requirements (digoxin, phospho...
Background Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activit...
WOS: 000252154900030PubMed ID: 17316845Background: Levosimendan is a novel positive inotropic calciu...
Background: Right ventricular (RV) dysfunction complicates advanced left ventricular (LV) heart fail...
Heart failure (HF) represents a deadly epidemic that nowadays affects more than 2% of the general po...
To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated ...
Background: Levosimendan, a novel calcium sensitiser, improves myocardial contractility without ...
BackgroundLevosimendan is a new inodilatory agent with calcium sensitizing activity. A major concern...
International audienceLevosimendan is a new inodilatory agent with calcium sensitizing activity. A m...
Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosime...
Mechanical alternans, an ominous sign of terminal systolic heart failure, could be indirectly shown ...
PubMed ID: 18786088Introduction: Although beta-blockers are highly effective in the treatment of hea...
Severe heart failure represents a major source of morbidity and mortality. Poor right ventricular fu...
WOS: 000252322200014PubMed ID: 17949428Objectives: Levosimendan is a novel positive inotropic calciu...
Background: Previous studies comparing levosimendan vs. dobutamine have revealed that levosimendan i...
In heart failure, positive inotropes that increase the heart's energy requirements (digoxin, phospho...
Background Levosimendan is a relatively new cardiac inotropic agent with calcium sensitizing activit...
WOS: 000252154900030PubMed ID: 17316845Background: Levosimendan is a novel positive inotropic calciu...
Background: Right ventricular (RV) dysfunction complicates advanced left ventricular (LV) heart fail...
Heart failure (HF) represents a deadly epidemic that nowadays affects more than 2% of the general po...
To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated ...
Background: Levosimendan, a novel calcium sensitiser, improves myocardial contractility without ...
BackgroundLevosimendan is a new inodilatory agent with calcium sensitizing activity. A major concern...
International audienceLevosimendan is a new inodilatory agent with calcium sensitizing activity. A m...
Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosime...